MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
* Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a sc...
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
MELBOURNE, Australia and INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...
* FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating68Ga-PSMA-PE...
* Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated...
* Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). * Approva...
* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-bio...
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent cle...
* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for...
* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured ...
* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-...
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...
* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose rea...
MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limi...
MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...